No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home COUNTRY UK&IRELAND

“Glucose is only the beginning”: London-based Sava Technologies raises €16.6 million for its wearable microsensor technology

EU Startupsby EU Startups
July 31, 2025
Reading Time: 3 mins read
in UK&IRELAND, VENTURE CAPITAL
Share on FacebookShare on Twitter

Sava Technologies Ltd., a British MedTech startup innovating real-time molecular health monitoring, today announced €16.6 million in Series A funding to accelerate regulatory approval and commercialisation of its next-generation wearable.

The round was led by Balderton Capital and Pentland Ventures, with participation from new investors Norrsken VC and JamJar Investments. They were joined by other investors including True, Italian Founders Fund, Athletico Ventures and Exceptional Ventures. Bringing Sava’s total funding to €27.9 million.

“This clinical trial marks a pivotal moment not just for Sava, but for the future of biosensing and personalised healthcare,” said Rafaël Michali, Co-founder and Co-CEO of Sava. “The data generated so far has shown that our technology has the potential to match the performance of leading CGMs in the market today, without the invasiveness or high cost of filament-based systems. It paves the way for a completely novel approach to biosensing that can redefine the way we approach not only chronic disease management, but any health goal.”

Founded in 2019 by Imperial College London bioengineers Renato Circi and Rafaël Michali, the team has developed a multi-molecule biosensor capable of detecting biomarkers just beneath the skin, in real-time. This proprietary technology is powering their first product – a pain-free Continuous Glucose Monitoring (CGM) device that streamlines molecular insights in real-time to your phone, at a fraction of the cost of current alternatives – as per the company.

Sava’s latest clinical trial, conducted independently by third-party investigators across sites in Oxford and Cambridge, involved 50 patients with Type 1 and insulin-dependent Type 2 diabetes.

As per data provided to EU-Startups, early results from the first 25 patients showed Sava’s proprietary technology delivered reliable, accurate glucose readings for up to 10 days of continuous wear – a milestone no other microsensor platform has allegedly been able to achieve to date. Most microsensor systems fail to last 5 days, and many struggle beyond 24 hours.

Today, only 1% of people with diabetes use CGMs, yet this group generates over €9.6 billion in annual sales, growing 10% year-on-year. Existing devices are often painful, expensive, and inaccessible.

“Understanding what’s going on in our bodies is the first step to improving our health,” said James Wise, Partner at Balderton. “Sava’s innovation has the potential to democratise access to glucose monitoring, as well as many other biomarkers, making them more practical for the millions of people who need them but can’t afford or tolerate the current options. Beyond diabetes, which alone is one of the greatest health challenges of our time, their platform opens the door to an entirely new era of personalised health monitoring.”

While tracking glucose is the first use case, Sava’s modular, multi-analyte sensing platform is claims to be capable of detecting additional molecules, providing users with the ability to unobtrusively monitor multiple biomarkers in real-time, paving the way for a future of preventative and personalised health.

“Glucose is only the beginning”, said Renato Circi, Co-founder and Co-CEO of Sava. “We have built a modular platform, capable of multi-molecule sensing. New molecules will create new use cases. What we’re building here is not just a device, but a whole new technological foundation for personalised healthcare, where anyone can use a biosensor to understand their health in real-time, at a molecular level.”

Sava’s team has grown to over 60+ people, including experts behind Abbott and Dexcom’s market-leading CGMs. The new capital will be used to further expand Sava’s team, advance automated manufacturing capabilities to reach target launch volumes, and accelerate the clinical validation of its microsensor technology.

Charlie Rubin, Investor at Pentland Ventures, added: “With its world-first technology, breakthrough clinical trial results, and new funding, Sava is positioned to lead the next wave of innovation in the $100B+ global health wearables market – beginning with CGM and creating a new market for real-time, multi-biomarker sensing. We are thrilled to be a part of the journey.”

Read the orginal article: https://www.eu-startups.com/2025/07/glucose-is-only-the-beginning-london-based-sava-technologies-raises-e16-6-million-for-its-wearable-microsensor-technology/

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

GREEN

Flox raises nearly $1M seed

August 8, 2025
SCANDINAVIA&BALTICS

Latvian startup receives €3.3 million to advance organ-on-chip technologies

August 8, 2025
DACH

Danish BioTech developer SNIPR Biome raises €35 million to target antimicrobial resistance in diseases like cancer

August 8, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

AlixPartners: Automotive, retail and manufacturing sectors may go through restructuring in 2025

AlixPartners: Automotive, retail and manufacturing sectors may go through restructuring in 2025

July 11, 2025
Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Next Post

Britain's cardiology diagnositics solution Ultromics raises €48 million to detect elusive forms of heart failure

Beyond the Atlantic: Why European startups should consider Africa for their next expansion

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart